KR20240155237A - 디페닐디아졸 유도체를 포함하는 약제학적 조성물 및 사용 방법 - Google Patents

디페닐디아졸 유도체를 포함하는 약제학적 조성물 및 사용 방법 Download PDF

Info

Publication number
KR20240155237A
KR20240155237A KR1020247029979A KR20247029979A KR20240155237A KR 20240155237 A KR20240155237 A KR 20240155237A KR 1020247029979 A KR1020247029979 A KR 1020247029979A KR 20247029979 A KR20247029979 A KR 20247029979A KR 20240155237 A KR20240155237 A KR 20240155237A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
anle138b
fatty acid
polyethylene glycol
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247029979A
Other languages
English (en)
Korean (ko)
Inventor
아르민 기제
요하네스 레빈
에마누엘라 델 베스코
Original Assignee
모다크 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모다크 게엠베하 filed Critical 모다크 게엠베하
Publication of KR20240155237A publication Critical patent/KR20240155237A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
KR1020247029979A 2022-03-01 2023-03-01 디페닐디아졸 유도체를 포함하는 약제학적 조성물 및 사용 방법 Pending KR20240155237A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22159408 2022-03-01
EP22159408.8 2022-03-01
PCT/EP2023/055160 WO2023166045A1 (en) 2022-03-01 2023-03-01 Pharmaceutical composition comprising diphenyldiazole derivatives and methods of use

Publications (1)

Publication Number Publication Date
KR20240155237A true KR20240155237A (ko) 2024-10-28

Family

ID=80623476

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247029979A Pending KR20240155237A (ko) 2022-03-01 2023-03-01 디페닐디아졸 유도체를 포함하는 약제학적 조성물 및 사용 방법

Country Status (12)

Country Link
US (1) US20250161273A1 (https=)
EP (1) EP4486340A1 (https=)
JP (1) JP2025508912A (https=)
KR (1) KR20240155237A (https=)
CN (1) CN118715010A (https=)
AU (1) AU2023227368A1 (https=)
CA (1) CA3246018A1 (https=)
CL (1) CL2024002379A1 (https=)
IL (1) IL314952A (https=)
MX (1) MX2024009773A (https=)
PE (1) PE20250781A1 (https=)
WO (1) WO2023166045A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025068949A1 (en) 2023-09-26 2025-04-03 Teva Pharmaceutical Industries Ltd. Emrusolmin for use in treating multiple system atrophy
KR20250090047A (ko) * 2023-12-12 2025-06-19 가천대학교 산학협력단 긴 탄소사슬을 포함하는 리파펜틴, 암포테리신 b, 세틸피리디늄, 도미펜, 토코페르솔란을 유효성분으로 포함하는 시누클레인병증 치료용 약제학적 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2687513B1 (en) * 2008-06-09 2020-12-02 Ludwig-Maximilians-Universität München Drugs for inhibiting aggregation of proteins involved in diseases linked to protein aggregation and/or neurodegenerative diseases
KR102671166B1 (ko) * 2015-12-14 2024-05-31 막스-플랑크-게젤샤프트 츄어 푀르더룽 데어 비쎈샤프텐 에.파우. 3,5-디페닐-디아졸 화합물의 수용성 유도체

Also Published As

Publication number Publication date
US20250161273A1 (en) 2025-05-22
CL2024002379A1 (es) 2025-01-24
WO2023166045A1 (en) 2023-09-07
EP4486340A1 (en) 2025-01-08
MX2024009773A (es) 2024-08-19
IL314952A (en) 2024-10-01
CA3246018A1 (en) 2023-09-07
AU2023227368A1 (en) 2024-07-18
JP2025508912A (ja) 2025-04-10
CN118715010A (zh) 2024-09-27
PE20250781A1 (es) 2025-03-14

Similar Documents

Publication Publication Date Title
TWI577392B (zh) ［（１ｓ）－１－｛［（２ｓ，４ｒ）－４－（７－氯－４－甲氧基異喹啉－１－基氧基）－２－（｛（１ｒ，２ｓ）－１－［（環丙基磺醯基）胺甲醯基］－２－乙烯基環丙基｝胺甲醯基）吡咯啶－１－基］羰基｝－２，２－二甲基丙基］胺基甲酸１，１－二甲基乙基酯之可溶性膠囊調配物
KR20240155237A (ko) 디페닐디아졸 유도체를 포함하는 약제학적 조성물 및 사용 방법
US20240189311A1 (en) Combination Therapy of Obicetrapib and Ezetimibe for Use in Statin Intolerant Patients Suffering from Hyperlipidemia or Mixed Dyslipidaemia
JP7314459B2 (ja) ３α－エチニル－３β－ヒドロキシアンドロスタン－１７－オンオキシムの医薬製剤
JP2022518356A (ja) レラコリラント含有医薬製剤、ヘテロアリールケトン縮合アザデカリン化合物
JP7120691B2 (ja) 非アルコール性脂肪肝炎の予防または治療用の薬学組成物
PT2407155E (pt) Formulações de inecalcitol
US20240165093A1 (en) Methods for treating familial chylomicronemia syndrome
HK40115748A (zh) 包含二苯基二唑衍生物的药物组合物及其使用方法
EA052714B1 (ru) Фармацевтическая композиция, содержащая производные дифенилдиазола, и способ применения
KR20240036651A (ko) 산화성 망막 질환의 진행을 억제하는 방법
UA110211C2 (uk) Нові склади 14-eпi-аналогів вітаміну d
JP2023552495A (ja) カンナビノイド作動薬を含む医薬組成物
EP4717262A1 (en) Pharmaceutical compositions of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid
JP3748912B2 (ja) オーレオバシジン類の高濃度溶液製剤
RU2779262C2 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ 3α-ЭТИНИЛ-3β-ГИДРОКСИАНДРОСТАН-17-ОНА ОКСИМА
RU2575819C2 (ru) Новые составы 14-эпи-аналогов витамина d
EP4719402A1 (en) Sparsentan for use in a method of treating iga-mediated diseases
AU2023333304A1 (en) Pharmaceutical compositions of d10-docosahexaenoic acid or esters thereof
EP4717261A1 (en) Pharmaceutical compositions of 2-(3,5-dichlorophenyl)-1,3-benzoxazole-6-carboxylic acid
RU2575792C2 (ru) Составы 14-эпи-аналогов витамина d
WO2024210195A1 (ja) 炎症性腸疾患の治療用医薬組成物
CN118742299A (zh) 监测患者对视网膜氧化性疾病治疗反应的方法
UA112845C2 (uk) Склад 14-eпi-аналогів вітаміну d
BR112016009008B1 (pt) Uso de estradiol e/ou hemi-hidrato de estradiol e de um agente solubilizante compreendendo um óleo de cadeia média para a preparação de um pessário para o tratamento de atrofia vulvovaginal e pessário que compreende estradiol

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000